Akeso-B (02256.HK): Bevacizumab receives FDA approval for the treatment of TGCT

Zhitong Finance APP news, Abbisko-B (02256.HK) announced that on November 11, 2026, the company's subsidiary Shanghai Abbisko Biotechnology Co., Ltd. (Abbisko Pharma) announced that PIMJETMI (generic name: pimicotinib hydrochloride capsules), a CSF-1R small molecule inhibitor, has received approval from the U.S. Food and Drug Administration (FDA) for the systemic treatment of adult patients with symptomatic tenosynovial giant cell tumor for whom surgical resection may result in worsening functional limitation or severe complications.